Dyne Therapeutics, Inc. (DYN) News
Filter DYN News Items
DYN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DYN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest DYN News From Around the Web
Below are the latest news stories about DYNE THERAPEUTICS INC that investors may wish to consider to help them evaluate DYN as an investment opportunity.
Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares FallDyne Therapeutics (DYN) said Friday that new clinical data from its ongoing phase 1/2 trial of DYNE- |
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust and sustained functional improvements; potential to support H1 2026 submission for U.S. Accelerated Approval - - DYNE-251 in Exon 51 DMD: Based on recent FDA feedback, pursuing U.S. Accelerated Approval with dystrophin as surrogate endpoint; data from ongoing Registrational Expansion Cohort in DELIV |
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 10:30 a.m. PT (1:30 p.m. ET). A live webcast will b |
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ETWALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report new clinical data from the Phase 1/2 ACHIEVE clinical trial on January 10, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Confere |
Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to AnalystsWe recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we are going to take a look at where Dyne Therapeutics Inc. (NASDAQ:DYN) stands against the other NASDAQ stocks. Potomac Wealth Advisors president Mark Avallone joined CNBC’s ‘The Exchange’ on November 16 to discuss where he […] |
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update- IND Application for DYNE-101 for DM1 Cleared by FDA - - New Clinical Data from DYNE-101 ACHIEVE Trial Expected in Early January 2025 - - Enrolling Registrational Cohort of DYNE-251 DELIVER Trial in DMD - WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third qua |
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases- Presentations Will Feature Recent Clinical Data From DYNE-251 and DYNE-101 as Well as Preclinical Data in FSHD and Pompe Disease - WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that previously reported clinical and preclinical data across its pipeline will be featured in poster prese |
Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy NowWe recently compiled a list of the 10 Best Hot Stocks To Buy Right Now. In this article, we are going to take a look at where Dyne Therapeutics, Inc. (NASDAQ:DYN) stands against the other hot stocks. While the market is seeing significant positives after the Fed rate cut, there have been some pressures. For example, […] |
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines ConferenceWALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference being held in New York on Monday, September 30, 2024 at 2:00 p.m. ET. A live webcast will be available in the Investors & M |
CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More SharesThose following along with Dyne Therapeutics, Inc. ( NASDAQ:DYN ) will no doubt be intrigued by the recent purchase of... |